Current use of autologous adipose tissue-derived stromal vascular fraction cells for orthopedic applications

October 4, 2017

Musculoskeletal injuries and damage are common health problems in both young and old patients. Various treatment modalities are available for such musculoskeletal injuries. However, most of these modalities provide only symptomatic relief. The regenerative potential of injured and damaged tissue with stem cells is a promising new treatment strategy in the field of orthopedics.

 

In an recent open review published on the Journal of Biomedical Science (31 January 2017), A group of scholars from South Korea reviewed available human clinical studies with regard to patient applications of autologous adipose SVF containing ASCs, specifically assessing effectiveness and safety in the field of orthopedic disorders. All studies reviewed in this article presents potential benefits of autologous adipose SVF in various orthopedic applications without any serious side effects.

 

In this open review, following key points are being covered: 

  • Autologous Adipose SVF

  • Current clinical applications of autologous adipose SVF in cartilage regeneration 

  • Current clinical application of autologous adipose SVF in bone regeneration 

  • Current clinical applications of autologous (or allogeneic) adipose SVF in tendon/ligament regeneration. 

 

Due to the current regulatory environment, culture expanded MSCs are considered to be a pharmaceutical product and require governmental clearance and approval. Autologous adipose SVF injection, on the other hand, is considered to be a medical procedure, and thus allowed in many parts of the world. Consequently, autologous adipose SVF is slowly being tried as an alternative treatment in the field of orthopedics, treating disorders involving cartilage, bone, and tendons/ligaments. Compared to bone marrow SVF, adipose tissue is considered to be a preferred source of MSCs in the form of SVF due to its ease of accessibility and the availability of a large number of stem cells per gram of adipose tissue. 

 

Autologous adipose SVF, containing MSCs that are termed ASCs, has a great clinical potential to treat various orthopedic disorders as seen in human studies. Along with autologous adipose SVF, double-blind, randomized human clinical trials are being conducted using culture expanded MSCs with promising results. Until culture expanded stem cells are available for various orthopedic applications, autologous adipose SVF may be worthwhile to try in individuals for whom medical treatment has failed and for whom surgical options are not available.

 

Click here to read the full paper. 

 

 

Interested to provide the newly invented regenerative therapies to your own clients? Dr Jeroen Stevens shares why you should join our Hands-On Master Class on Stem Cell & PRP Therapy. Watch his welcome message below: 

 

 

 

Region's 1st Hands-On Master Class on 

Stem Cell & PRS Therapy for Facial Rejuvenation & Sports Medicine​

 

  • 2 Days Power Packed Training Program:​ Theory + Live Demonstration + Hands-on Training

  • 6 Live Demonstration Cases Showing Step-By-Step Procedure 

  • 6 Hours Hands-On Training with Maximum Live Patients Practice Experience 

  • Gain Proficiency to Perform and Launch New Procedures Right After the Training 

  • Become Region's Pioneer on stem cell and PRS Therapy for facial rejuvenation and sports medicine with No/Minimum Competitions 

 

Available Master Class Dates and Venues

  • Nov 13-14, 2017, Hong Kong, China   Details  (Selling Fast) 

  • Feb 4-5, 2017  Miami, FL, United States   Details  (Newly Opened) 

 

Register Now! 

Check out other upcoming IFAAS global events 

 

 

 

 

 

 

 

 

Please reload

Recent Posts

Please reload

Archive

Please reload

Tags